LeMaitre Vascular Announces Details for Its December 3rd Investor and Analyst Day
November 30 2015 - 5:06PM
LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral
vascular devices and implants, announced today that it will webcast
its investor and analyst day to be held on December 3, 2015 at
Ruth’s Chris Steakhouse in New York City.
This event is open to all investors and analysts. It will
feature presentations by senior management who will discuss the
Company's positioning, corporate strategy and growth opportunities
followed by question and answer sessions. During the event,
the Company plans to reiterate its financial outlook for the fourth
quarter and full year 2015 that it previously announced on October
27, 2015.
To RSVP for in-person attendance, please email Kimberly Cieslak
at kcieslak@lemaitre.com.
A webcast will be available live on the Investor Relations page
of the Company's website at www.lemaitre.com/investor. A recorded
replay of the webcast will be available on the same Investor
Relations page shortly after the conclusion of the event.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices and implants for the
treatment of peripheral vascular disease, a condition that affects
more than 20 million people worldwide. The Company develops,
manufactures and markets disposable and implantable vascular
devices to address the needs of its core customer, the vascular
surgeon. The Company's diversified product portfolio consists of
brand name devices used in arteries and veins outside of the
heart. Additional information can be found at
http://www.lemaitre.com.
LeMaitre and the LeMaitre Vascular logo are registered
trademarks of LeMaitre Vascular, Inc.
Forward-Looking Statements
Statements made in this release may be forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such "forward-looking statements"
regarding the Company's business that are not historical facts may
involve risks and uncertainties. Forward-looking statements are
based on management's current, preliminary expectations and are
subject to risks and uncertainties that could cause actual results
to differ from the results predicted. These risks and uncertainties
include, but are not limited to, the risk that the Company may not
realize the anticipated benefits of its strategic activities; the
risk that assumptions about the market for the Company’s products
and the productivity of the Company’s direct sales force and
distributors may not be correct; risks related to the integration
of acquisition targets; risks related to product demand and market
acceptance of the Company’s products and pricing; the risk that the
XenoSure product is not as accretive and does not achieve the gross
margins currently anticipated by the Company; the risk that the
Company is not successful in transitioning to a direct-selling
model in new territories; adverse or fluctuating conditions in the
general domestic and global economic markets and other risks and
uncertainties included under the heading "Risk Factors" in its most
recent Annual Report on Form 10-K, as updated by its subsequent
filings with the SEC, all of which are available on the Company's
investor relations website at http://www.lemaitre.com and on the
SEC's website at http://www.sec.gov. Undue reliance should not be
placed on forward-looking statements, which speak only as of the
date they are made. The Company undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events, or circumstances after the date they were made, or to
reflect the occurrence of unanticipated events.
LeMaitre Vascular, Inc.
Kimberly Cieslak
+1-781-425-1653
kcieslak@lemaitre.com
http://www.lemaitre.com
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From Sep 2023 to Sep 2024